These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18382132)

  • 41. Transfusion-related transmission of yellow fever vaccine virus--California, 2009.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Jan; 59(2):34-7. PubMed ID: 20094025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru: A Randomized Trial.
    López P; Lanata CF; Zambrano B; Cortés M; Andrade T; Amemiya I; Terrones C; Gil AI; Verastegui H; Marquez V; Crevat D; Jezorwski J; Noriega F
    Pediatr Infect Dis J; 2016 Oct; 35(10):1140-7. PubMed ID: 27254034
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.
    Sidibe M; Yactayo S; Kalle A; Sall AA; Sow S; Ndoutabe M; Perea W; Avokey F; Lewis RF; Veit O
    Trans R Soc Trop Med Hyg; 2012 Jul; 106(7):437-44. PubMed ID: 22627101
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas].
    Dabrowska MM; Flisiak R
    Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast.
    Fitzner J; Coulibaly D; Kouadio DE; Yavo JC; Loukou YG; Koudou PO; Coulombier D
    Vaccine; 2004 Nov; 23(2):156-62. PubMed ID: 15531032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Factors associated with severity of adverse events following yellow fever vaccination during the biggest outbreak of the disease recorded in Brazil, 2016-2017.
    Lucena ARFP; Souza LRO; Percio J; Carvalho SMD; Romano APM; Domingues CMAS
    Epidemiol Serv Saude; 2020; 29(1):e2018331. PubMed ID: 32215531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suspected YF-AND after yellow fever vaccination in Finland.
    Jääskeläinen AJ; Huhtamo E; Kivioja R; Domingo C; Vene S; Kallio-Kokko H; Niedrig M; Tienari PJ; Vapalahti O
    J Clin Virol; 2014 Nov; 61(3):444-7. PubMed ID: 25223921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Yellow fever vaccines and international travelers.
    Barnett ED; Wilder-Smith A; Wilson ME
    Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue].
    Gómez SY; Ocazionez RE
    Rev Salud Publica (Bogota); 2008; 10(5):796-807. PubMed ID: 19360228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
    Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
    Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.
    Nzolo D; Engo Biongo A; Kuemmerle A; Lusakibanza M; Lula Y; Nsengi N; Nsibu Ndosimao C; Tona Lutete G; Van Geertruyden JP
    Vaccine; 2018 Oct; 36(41):6170-6182. PubMed ID: 30190119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular characterization of the 17D-204 yellow fever vaccine.
    Salmona M; Gazaignes S; Mercier-Delarue S; Garnier F; Korimbocus J; Colin de Verdière N; LeGoff J; Roques P; Simon F
    Vaccine; 2015 Oct; 33(41):5432-5436. PubMed ID: 26314624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Long term persistence of yellow fever neutralising antibodies in elderly persons].
    Coulange Bodilis H; Benabdelmoumen G; Gergely A; Goujon C; Pelicot M; Poujol P; Consigny PH
    Bull Soc Pathol Exot; 2011 Oct; 104(4):260-5. PubMed ID: 21336654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Yellow fever vaccination: update on rare and severe adverse effects].
    Receveur MC; Bruyand M; Pistone T; Malvy D
    Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013--recommendations.
    Who
    Vaccine; 2015 Jan; 33(1):76-7. PubMed ID: 24852721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
    Valim V; Machado KLLL; Miyamoto ST; Pinto AD; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Dias JGF; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; da Costa-Rocha IA; de Lima SMB; Miranda EH; Trindade GF; Maia MLS; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Casagrande TZ; Oliveira KG; Moura BCDM; Nicole-Batista F; Rodrigues LC; Clemente TB; Magalhães ES; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Costa CZ; Giovelli RA; Brandão LR; Polito ETL; Koehlert IO; Borjaille BP; Pereira DB; Dias LH; Merlo DL; Genelhu LFF; Pretti FZ; Giacomin MDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Martins-Filho OA
    Front Immunol; 2020; 11():1382. PubMed ID: 32765496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
    Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.